about
Incorporated in 1978, Biocon is engaged in the manufacture of biotechnology products and research services. The company's business include Generics with diverse portfolio encompasses a wide range of complex molecules, including cardiovascular medicat...
Read More
352.00
-6.30
(-1.76%)
2.6M
NSE+BSE Volume
NSE 28 Aug, 2025 3:30 PM (IST)
US FDA Approval
Biocon receives US FDA tentative approval for Sitagliptin Tablets, with a market size of $6.9 bn
See details